Top Stories
Top Stories
Biotech and Pharma

Novartis to answer US Senate demand for data manipulation details

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016.
Scott Eisen | Bloomberg | Getty Images

Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.

"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.

U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.

Novartis, which won approval for Zolgensma in May — more than a month before it told the Food and Drug Administration of the alleged data fraud — has terminated several scientists amid an internal investigation.

Next Article
Key Points
  • Alphabet's Google has shut down a service it provided to wireless carriers globally that showed them weak spots in their network coverage, people familiar with the matter told Reuters.
  • Google is concerned that sharing data from users of its Android phone system might attract the scrutiny of users and regulators.
  • Google's Mobile Network Insights service, which had launched in March 2017, was essentially a map showing carriers signal strengths and connection speeds they were delivering in each area.